Novartis' Exjade Recommended For Approval Under Broader Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Blood Products Advisory Committee agreed that data for the oral chelating agent from primarily thalassemia patients may be extrapolated to transfusional hemosiderosis.You may also be interested in...
Lilly’s Gemzar For Ovarian Cancer To Be Reviewed by Oncologic Cmte.
FDA’s Oncologic Drugs Advisory Committee will review Gemzar on March 15. The committee’s Pediatric Oncology Subcommittee will discuss Novartis’ Exjade post-marketing study commitments on March 14.
Lilly’s Gemzar For Ovarian Cancer To Be Reviewed by Oncologic Cmte.
FDA’s Oncologic Drugs Advisory Committee will review Gemzar on March 15. The committee’s Pediatric Oncology Subcommittee will discuss Novartis’ Exjade post-marketing study commitments on March 14.
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: